Search
Results: 1
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM)
Seerapani Gopaluni, Rona M Smith, Michelle Lewin, Carol A McAlear, Kim Mynard, Rachel B Jones, Ulrich Specks, Peter A Merkel, David RW Jayne, RITAZAREM Investigators
May 05, 2017
BACKGROUND: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates...
ANCA-associated vasculitis Azathioprine RITAZAREM Randomized clinical trial Rituximab Administration Intravenous Administration Oral Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Australia Azathioprine Clinical Protocols Europe Glucocorticoids Humans Immunosuppressive Agents Japan Maintenance Chemotherapy New Zealand Recurrence Remission Induction Research Design Rituximab Time Factors Treatment Outcome